Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: Impact of area under the curve/MIC ratios on eradication

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 1, 2002, Pages 69-74

  Lister, P D ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; COLONY FORMING UNIT; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 0036136636     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.1.69-74.2002     Document Type: Article

References (18)

1. Two compartment kinetic model with multiple artificial capillary units
2. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophitus influenzae, and Moraxella catarrhalis
3. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY antimicrobial surveillance program
4. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas aeruginosa sepsis
5. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones
6. The meaurement of antibiotics in human fluids: Techniques and significance
7. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute acterial exacerbations of chronic bronchitis
8. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
9. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
10. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
11. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
12. Cefepimeaztreonam: A unique double β-lactam combination for Pseudomonas aeruginosa
13. Antimicrobial activity of gatifloxacin (AM-1155, CG5501) and four other fluoroquinolones tested against 2,284 recent clinical isolates Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States
14. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
15. Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
16. Awakening the slumbering potential of the 4-quinolone antibacterials
17. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads